Keywords: Prevention | Depression | Behavioral Medicine
Presentation Type: Symposium
Depression is a debilitating illness that affects a significant number of people worldwide and results in high costs to both individuals and society. CB has demonstrated efficacy in preventing depression in the general population without known risk factors, in people with known risk factors for the illness, and in those with sub-clinical symptoms of depression. A few studies have shown that CBT is also effective in preventing depression in individuals with medical illnesses. However, investigating if CB can prevent depression triggered by pharmacological substances is a relatively new area of research. Objective: The present pilot study evaluated an augmented cognitive behavioral intervention as a preventive intervention for depression using a randomized, controlled design in an economically disadvantaged, largely minority sample who were at risk to develop depression as a side-effect to a pharmacological substance (Interferon therapy for hepatitis C). Methods Patients (N=18) were seen in the primary clinics of an academic hospital that primarily serves a low income, minority population. The intervention group (N=12) received an eight-session augmented group CB intervention while the control group received eight support group sessions. Results: Results demonstrated that this augmented CB intervention was feasible in this population and was delivered with high degree of integrity. On average, 66% of participants attended each session of the intervention group while 50% attended each session of the support group. Sixty-six percent in the intervention group versus only 16% participants remained on interferon therapy at the end of group sessions. Although depressive symptoms between the intervention and control groups were not statistically different F(1)=2.44, p=.14), the plotted data indicate a trend for participants in the intervention group to report lower levels of depression than those in the control group. Discussion: The study demonstrated that an enhanced non-pharmacological prevention intervention such is feasible for use in patients at risk for developing pharmacologically induced depression and may reduce the symptoms of depression that develop as a side effect to taking these medications. Future studies should use larger samples and test the augmented CB intervention in other populations.
Cognitive & Behavioral Consultants
Saturday, November 18
12:00 PM – 1:30 PM
The asset you are trying to access is locked. Please enter your access key to unlock.